Holen Sie sich die Stockscreener-App
1.96
5.38%
0.10
Schlusskurs vom Vortag:
$1.86
Offen:
$1.89
24-Stunden-Volumen:
420.40K
Relative Volume:
0.36
Marktkapitalisierung:
$75.39M
Einnahmen:
$55,200
Nettoeinkommen (Verlust:
$-19.39M
KGV:
-3.0659
EPS:
-0.6393
Netto-Cashflow:
$-17.30M
1W Leistung:
+0.51%
1M Leistung:
-22.22%
6M Leistung:
+13.29%
1J Leistung:
-14.04%
1-Tages-Spanne:
$1.8899
$2.02
1-Wochen-Bereich:
$1.79
$2.09
52-Wochen-Spanne:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.96 | 71.54M | 55,200 | -19.39M | -17.30M | -0.6393 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
GANX: Disease-modifying Parkinson's therapy advances to phase II with strong biomarker support - TradingView
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference - MarketBeat
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Aug Volume: Is RDFN stock a buy or sell2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Market Moves: What hedge funds are buying Gain Therapeutics IncWeekly Gains Report & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Published on: 2026-03-21 10:38:36 - baoquankhu1.vn
Can Gain Therapeutics Inc outperform in the next rallyTrade Entry Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Gain Therapeutics to Present at the 38th Annual ROTH Conference - The Manila Times
Gain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH Conference - Quiver Quantitative
Gain CEO Gene Mack to speak at ROTH conference on March 23 - Stock Titan
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday - Defense World
Gain Therapeutics reports biomarker data from Parkinson’s trial By Investing.com - Investing.com South Africa
Gain announces presentations on Phase 1b clinical study of GT-02287 - TipRanks
Gain Therapeutics, Inc. (GANX): Emerging Biomarker Data Strengthens Parkinson’s Drug Pipeline - parameter.io
Gain Therapeutics Presents Positive Phase 1b Results for GT-02287 in Parkinson’s Disease and Advances New GCase Modulators for Clinical Development 123 - Minichart
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data - TipRanks
Gain Presents Phase 1b GT-02287 Data Showing biomarker changes, MDS-UPDRS stability; GT-04686 ready for IND - TradingView
Gain Therapeutics (NASDAQ: GANX) unveils new Parkinson’s trial and biomarker data - Stock Titan
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 - Bitget
Gain Therapeutics reports biomarker data from Parkinson’s trial - Investing.com
Parkinson’s trial drug sees symptoms hold steady over 5 months - Stock Titan
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can Gain Therapeutics Inc stock double in the next yearWeekly Investment Summary & Expert Curated Trade Ideas - baoquankhu1.vn
Aug Drivers: Whats the beta of Gain Therapeutics Inc stock2026 Weekly Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7%What's Next? - MarketBeat
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next? - Defense World
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Gain Therapeutics (GANX) upgraded to buy: Here's why - MSN
Is Gain Therapeutics Inc vulnerable to short sellersWeekly Profit Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - Bitget
Experimental Parkinson’s drug GT-02287 moves toward Phase 2 test - Stock Titan
Market Recap: Is Gain Therapeutics Inc part of any major indexWeekly Gains Report & Risk Managed Investment Signals - baoquankhu1.vn
GANX Technical Analysis & ETF Price Forecast - Intellectia AI
What makes Gain Therapeutics Inc. stock attractive to growth fundsCEO Change & Expert Curated Trade Ideas - Naître et grandir
Pharma News: Can Gain Therapeutics Inc continue delivering strong returnsMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Bearish Setup: What is Gain Therapeutics Incs 5 year growth outlookTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
GANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Voyager Therapeutics Inc. stock gain from lower inflationTrade Analysis Report & Daily Oversold Stock Bounce Ideas - mfd.ru
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
GANX PE Ratio & Valuation, Is GANX Overvalued - Intellectia AI
Intellia Therapeutics Opens with 6.49% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Gain Therapeutics to Present Key Clinical Program Updates at Oppenheimer Conference - AD HOC NEWS
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - 富途牛牛
What’s the beta of Gain Therapeutics Inc. stock2025 Short Interest & Detailed Earnings Play Alerts - mfd.ru
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):